Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) CEO Marshall Fordyce sold 14,471 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $39.76, for a total transaction of $575,366.96. Following the transaction, the chief executive officer now directly owns 322,667 shares of the company’s stock, valued at approximately $12,829,239.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Vera Therapeutics Price Performance
NASDAQ:VERA traded up $0.18 during mid-day trading on Friday, hitting $39.30. The company’s stock had a trading volume of 301,331 shares, compared to its average volume of 962,849. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -19.12 and a beta of 0.99. The stock has a fifty day moving average of $36.24 and a 200-day moving average of $39.94. The company has a current ratio of 21.43, a quick ratio of 21.43 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a fifty-two week low of $9.24 and a fifty-two week high of $50.78.
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). As a group, equities analysts forecast that Vera Therapeutics, Inc. will post -2.59 EPS for the current fiscal year.
Institutional Trading of Vera Therapeutics
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on the stock. Raymond James increased their price target on shares of Vera Therapeutics from $57.00 to $68.00 and gave the stock a “strong-buy” rating in a research report on Friday, May 10th. JPMorgan Chase & Co. dropped their price target on shares of Vera Therapeutics from $65.00 to $62.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $42.43.
Get Our Latest Stock Analysis on Vera Therapeutics
Vera Therapeutics Company Profile
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Featured Articles
- Five stocks we like better than Vera Therapeutics
- When to Sell a Stock for Profit or Loss
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- Learn Technical Analysis Skills to Master the Stock Market
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- Most active stocks: Dollar volume vs share volume
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.